Study of Escitalopram in the Treatment of Specific Phobia

Phase 2

Completed

• Conditions: Phobic Disorders

• Registration Number: NCT00121069
• Lead Sponsor: Connor, Kathryn M., M.D.

Brief Summary

This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.

Detailed Description

This double-blind placebo-controlled pilot trial study is designed to assess the efficacy of 12 weeks of escitalopram vs. placebo in the treatment of specific phobia in adult outpatients. It is hypothesized that escitalopram is safe and effective in the treatment of specific phobia.

Study Timeline

• Study Start: 2002-09
• Study Completion: 2004-09
• Status Verified: 2005-07
• Study First Submitted: 2005-07-13
• Study First Submitted QC: 2005-07-19
• Last Update Submitted: 2005-07-19
• Study First Posted: 2005-07-21
• Last Update Posted: 2005-07-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Adults 18-65 years of age
• DSM-IV criteria for specific phobia according to the MINI
• For women of childbearing potential, a negative serum pregnancy test at screening
• Written informed consent

Exclusion Criteria

• Any current primary DSM-IV diagnosis other than specific phobia
• History of DSM-IV substance abuse or dependence within the last months
• Lifetime history of bipolar I disorder, schizophrenia or other psychotic disorder, mental retardation, or other pervasive developmental disorder or cognitive disorder due to a general medical condition
• Suicide risk or serious suicide attempt within the last year
• Clinically significant laboratory or EKG abnormality or unstable medical condition
• For women of childbearing potential, unwillingness to use an acceptable form of contraception during the study
• Subjects needing concurrent use of psychotropic medications

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Response based on a criterion of 50% or greater reduction in the Marks Main Phobia Questionnaire and Marks Fear Questionnaire from baseline

Secondary Outcome Measures

Name	Time	Method
Response based on CGI-I category

Trial Locations

Locations (1)

Dept of Psychiatry and Behvaioral Science, Duke Unviersity Medical Center; 🇺🇸 Durham, North Carolina, United States